DK3399040T3 - Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme - Google Patents

Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme Download PDF

Info

Publication number
DK3399040T3
DK3399040T3 DK15911682.1T DK15911682T DK3399040T3 DK 3399040 T3 DK3399040 T3 DK 3399040T3 DK 15911682 T DK15911682 T DK 15911682T DK 3399040 T3 DK3399040 T3 DK 3399040T3
Authority
DK
Denmark
Prior art keywords
procedure
preparation
pharmaceutical composition
same
composition including
Prior art date
Application number
DK15911682.1T
Other languages
English (en)
Inventor
Jiunn-Horng Lin
Zeng-Weng Chen
Jyh-Perng Wang
Tzu-Ting Peng
Huei-Yu Lee
Weng-Zeng Huang
Shih-Rong Wang
Cheng-Yao Yang
Original Assignee
Agricultural Tech Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agricultural Tech Res Inst filed Critical Agricultural Tech Res Inst
Application granted granted Critical
Publication of DK3399040T3 publication Critical patent/DK3399040T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15911682.1T 2015-12-28 2015-12-28 Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme DK3399040T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/099172 WO2017113050A1 (zh) 2015-12-28 2015-12-28 猪圆环病毒2型的外鞘蛋白质的制备方法及含该外鞘蛋白质的医药组合物

Publications (1)

Publication Number Publication Date
DK3399040T3 true DK3399040T3 (da) 2021-08-30

Family

ID=59224021

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15911682.1T DK3399040T3 (da) 2015-12-28 2015-12-28 Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme

Country Status (11)

Country Link
US (1) US10767185B2 (da)
EP (1) EP3399040B1 (da)
JP (1) JP6629975B2 (da)
KR (1) KR102055215B1 (da)
CN (1) CN108026538B (da)
CA (1) CA3009903C (da)
DK (1) DK3399040T3 (da)
ES (1) ES2881625T3 (da)
PH (1) PH12018501183A1 (da)
RU (1) RU2701816C1 (da)
WO (1) WO2017113050A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220296697A1 (en) * 2019-08-20 2022-09-22 Km Biologics Co., Ltd. Porcine circovirus type 2 vlp vaccine
PE20211141A1 (es) * 2019-12-19 2021-06-25 Farm Veterinarios S A C Salmonella enteritidis recombinante y su uso como vacuna porcina
CN111455470A (zh) * 2020-04-09 2020-07-28 嘉兴菲沙基因信息有限公司 一种可以提升Hi-C文库数据质量的小片段DNA文库构建方法
KR102438044B1 (ko) * 2020-06-17 2022-09-01 대한민국 재조합 제2형 돼지써코바이러스 항원 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049378A (en) * 1989-04-24 1991-09-17 Ciba-Geigy Canada Ltd. Prevention and treatment of porcine haemophilus pneumonia (PHP)
WO1992020791A1 (en) * 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CN1242427A (zh) * 1998-07-17 2000-01-26 上海华晨生物技术研究所 克隆、表达及测序一体化载体及其用途
WO2002060921A2 (en) * 2000-11-09 2002-08-08 Board Of Trustees Of The University Of Illinois Enhancement of immune response to vaccine by interferon alpha
CN1579553A (zh) * 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
CN104383526B (zh) * 2005-12-29 2018-09-18 贝林格尔.英格海姆维特梅迪卡有限公司 Pcv2免疫原性组合物用于减轻猪临床症状的用途
EP2094872B2 (en) * 2006-12-15 2020-02-19 Boehringer Ingelheim Animal Health USA Inc. Treatment of anti-PCV2 antibody seropositive pigs with PCV2 antigen
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7833533B2 (en) * 2008-04-24 2010-11-16 The United States Of America As Represented By The Secretary Of Agriculture Enhanced antiviral activity against foot and mouth disease
AU2009243871A1 (en) * 2008-05-09 2009-11-12 University Of Saskatchewan Phage lambda display constructs
US20100150959A1 (en) * 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
CN101845419B (zh) * 2010-05-20 2011-08-17 广东大华农动物保健品股份有限公司 一种重组腺病毒及其应用
CN102839189A (zh) * 2012-07-18 2012-12-26 华南农业大学 利用pCold-sumo表达载体高效表达PCV 2 Cap蛋白的方法
CN102994518A (zh) * 2012-12-04 2013-03-27 山东信得科技股份有限公司 一种猪ii型圆环病毒orf2蛋白的制备方法
CN103059124B (zh) * 2012-12-31 2014-02-12 江苏众红生物工程创药研究院有限公司 一种重组猪干扰素γ及其编码基因和表达方法
KR101764750B1 (ko) * 2013-02-05 2017-08-03 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 항-마이코플라즈마 에스피피. 아단위 백신
KR101488362B1 (ko) * 2013-08-14 2015-02-02 국립대학법인 울산과학기술대학교 산학협력단 글루코스 및 자일로스를 동시에 이용할 수 있는 변이대장균의 제조방법

Also Published As

Publication number Publication date
RU2701816C1 (ru) 2019-10-01
CA3009903C (en) 2021-02-23
EP3399040A4 (en) 2019-05-15
KR20180082594A (ko) 2018-07-18
ES2881625T3 (es) 2021-11-30
JP6629975B2 (ja) 2020-01-15
EP3399040B1 (en) 2021-07-14
CN108026538B (zh) 2021-09-03
US10767185B2 (en) 2020-09-08
EP3399040A1 (en) 2018-11-07
CA3009903A1 (en) 2017-07-06
BR112018013007A2 (pt) 2018-12-04
JP2019504047A (ja) 2019-02-14
PH12018501183A1 (en) 2019-01-28
WO2017113050A1 (zh) 2017-07-06
US20190078101A1 (en) 2019-03-14
KR102055215B1 (ko) 2020-01-22
CN108026538A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
DK3684423T3 (da) Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
DK3445773T3 (da) Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
DK3402499T3 (da) Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes
DK3528825T3 (da) Fremgangsmåder og sammensætninger til ændring af sammensætningen af hudmikrobiomet under anvendelse af komplekse blandinger af bakteriestammer
DK3298033T4 (da) Sammensætninger og medicinske anvendelser til tcr-reprogrammering under anvendelse af fusionsproteiner
SG11202009150RA (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
EP3288543A4 (en) Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
DK3312177T3 (da) Tricyklisk derivatforbindelse, fremgangsmåde til at fremstille samme og farmaceutisk sammensætning omfattende samme
DK3286181T3 (da) Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
EP3142645A4 (en) Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3277270T3 (da) Sammensætninger og fremgangsmåder til behandling af anæmi
DK3785733T3 (da) Farmaceutisk sammensætning til behandling af autisme
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
DK3744316T3 (da) Oftalmisk farmaceutisk sammensætning, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3468964T3 (da) Modulatorer af SOCE, sammensætninger og anvendelser deraf
DK3399040T3 (da) Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme
DK3522873T3 (da) Sammensætninger og fremgangsmåder til behandlingen af xerostomi
DK3672631T3 (da) Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3404033T3 (da) C-glukosidderivat med kondenseret phenylring eller farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende dette